Therapeutic interruption of PRPS2 function through developing inhibitors that selectively bind to its distinctive Loop2 region for enzymatic inhibition, or protein-protein interaction (PPI)-based inhibitors to disrupt the PRPS2-MAT2A association could disrupt nucleotide biosynthesis and RNA epigenetic methylation, which are essential for tumor progression. The gene discussed is MAT2A; the disease is neoplasm.